Who We Are

Sirnaomics is the first to achieve positive Phase IIa clinical outcomes in oncology clinical-stage RNA therapeutics biopharmaceutical company with a strong presence in both China and the U.S. that is discovering and developing innovative drugs for indications with significant unmet medical needs and large market opportunities. We have built a professional international team for the discovery and development of RNAi therapeutics and mRNA vaccines and therapeutics, based on our proprietary drug delivery technology platforms.

map map
Boston – BD center
Beijing – China Clinical Center
Suzhou – China Headquarter, R&D Hub
Guangzhou – Clinical Manufacturing Facility
Hong Kong – Financing & IR
Laguna Niguel, CA – US Clinical Center
Gaithersburg – Global Headquarter

Leadership Team

Dr. Patrick Y. Lu
Chairman of the Board, Executive Director, President & Chief Executive Officer
Dr. Michael V. Molyneaux
Executive Director, Chief Medical Officer
Dr. David Mark Evans
Executive Director, Chief Scientific Officer
Dr. Steven Long
Chief Development Officer
Dr. Dmitry Samarsky
Chief Technology Officer
Dr. Edward Wang
Chief Production Officer
Dr. Richard W. Welch
Vice President, CMC
Dr. Jacqueline A. Dombroski
Vice President, Regulatory Affairs
Mr. Nigel Yip
China Chief Financial Officer, Vice President of Corporate Finance
Ms. Monica Zhang
China Chief Operating Officer, Board Secretary, Joint Company Secretary
Mr. George Ji
Chief Operation Officer
Mr. John Buergenthal
Vice President, Human Resources

Our Story

KEY BUSINESS MILESTONES

2022

Initiated Phase Ⅰ/Ⅱ clinical trial of STP705 in the U.S. for Facial isSCC

Obtained IND clearance from the Taiwan Ministry of Health and Welfare for STP705 in Liver Cancer Treatment

Initiated Phase Ⅰ clinical trial of STP705 in the U.S. for Medical Cosmetology Treatment

Initiated Phase Ⅰ clinical trial of STP707 in the U.S. for Primary sclerosing cholangitis

Initiated Phase Ⅰ clinical trial of STP707 in the U.S. for Solid tumors

2021

Became public on the Main Board of The Stock Exchange of Hong Kong Limited

Established a co-development partnership for STP702 with Walvax

Completed Series E financing, raising approximately US$107 million

Initiated Phase Ⅱb study in the U.S. for STP705 in squamous cell carcinoma in situ

Initiated Phase Ⅱ clinical trial in the U.S. for STP705 for keloid scarless healing

Initiated Phase Ⅰ clinical trial in the U.S. for STP705 for liver cancer

Obtained “acceptance for review” from the NMPA in China for STP705 in squamous cell carcinoma in situ

Obtained IND clearance from the U.S. FDA for STP707

Established a manufacturing facility with fill and finish capacity in Guangzhou, to produce large-scale products with GMP compliance

Started the construction of the southern headquarters of Sirnaomics

2020

Launched RNAimmune, a subsidiary of Sirnaomics

Completed a Series D round of financing, totaling approximately US$104 million

Completed a Phase Ⅰ/Ⅱ study in the U.S. for STP705 in squamous cell carcinoma in situ

Initiated a Phase Ⅱ clinical trial in the U.S. for STP705 in basal cell carcinoma

Sirnaomics Guangzhou obtained the national innovation company certification in China again

2019

Completed a Series C round of financing, totaling US$48 million

Established Sirnaomics Hong Kong

2018

Obtained IND clearance from the U.S. FDA for STP705 in advanced cholangiocarcinoma

Received FDA clearance for Phase Ⅱ study of STP705 for squamous cell carcinoma nonmelanoma skin cancer

2017

Completed a Series B round of financing, totaling US$10 million

Achieved the first IND approval of STP705 for treating hypertrophic scars in China

STP705 granted orphan drug designation by the U.S. FDA for the treatment of Cholangiocarcinoma and primary sclerosing cholangitis

Sirnaomics Guangzhou obtained the national innovation company certification in China

Sirnaomics Guangzhou partnered with Jiangsu Zhengyuan to develop a variety of atomization drug delivery devices

2016

Obtained IND clearance from the U.S. FDA for a Phase Ⅱa clinical study of STP705 in hypertrophic scars

2015

Sirnaomics Suzhou and Sirnaomics Guangzhou were selected as the “Significant New Drug Creation” in the 13th Five-Year Plan for national economic and social development in China

2014

Submitted an IND application to the China Food and Drug Administration for STP705 for the treatment of hypertrophic scars, which would be China's first nucleic acid drug if approved

2013

Sirnaomics Suzhou and Sirnaomics Guangzhou were selected as the “Significant New Drug Creation” in the 12th Five-Year Plan for national economic and social development in China

2012

Expanded presence in China with new offices in Guangzhou, China

Sirnaomics Guangzhou was selected as the Guangzhou Entrepreneurship Leading Talent Project

2009

Sirnaomics’ Suzhou was selected as a Jiangsu Science and Technology Leading Talent Project

Sirnaomics Suzhou was certified as the Suzhou Engineering Research Center for nucleic acid drugs by the Suzhou Science and Technology Bureau

2008

Established Sirnaomics’ China headquarters in Suzhou

2007

Established Sirnaomics’ U.S. headquarters in Gaithersburg, Maryland

Awards & Recognitions
2017

Small Giant Enterprise in

Science and Technology of

Guangzhou Province of 2016

Guangzhou Science Technology and Innovation Commission

2017

Third Prize of the 6th National Innovation & Entrepreneurship Competition

(Biopharmaceutical Growth Group)

National Innovation & Entrepreneurship Competition Committee

2017

National New and Advanced

Technology Enterprise

National Office of Leading Group for Administration of Hi-tech Enterprise Recognition

2020

National New and Advanced

Technology Enterprise

National Office of Leading Group for Administration of Hi-tech Enterprise Recognition

2021

Top 10 RNA-Based Biopharmas

Genetic Engineering and Biotechnology News

2021

Top 3 finalists of

Skin Health Innovation Competition

Gore Range Capital

2022

The Listed Enterprise

Excellence Awards 2021

Capital Magazine

Patents
Our patents and patent applications span methods of delivering RNAi triggers and mRNA to cells, compositions of matter and devices used in our RNAi and mRNA delivery platforms, siRNA or RNAi trigger compositions, manufacturing processes, and usage and indications. Current Patents include:
img

9issued patents in China

img

9issued patents in the U.S.

img

2issued patents in Europe 

img

119pending patent applications, including:

19 Chinese patent applications

43 U.S. patent applications

(including 32 U.S. provisional patent applications)

8 patent applications under the Patent Cooperation Treaty

6 patent applications in Europe

43 patent applications in other jurisdictions.

Contact Us
Sirnaomics, Inc.

401 Professional Dr, STE 280 Gaithersburg, MD 20879, USA

+1 301-740-1730
Sirnaomics, Suzhou

218 Xinghu Street, STE A4-415 BioBay, Suzhou, China

+86 512 62956283
Sirnaomics, Guangzhou

12 Luoxuan 3 Road, STE 4-306 Guangzhou International Bio-island Guangzhou, China

+86 20 84229842
Sirnaomics, Hong Kong

46/F, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, China

+852 3180 9494
Sirnaomics, Boston

245 First Street, 18F
Cambridge, MA 02142, USA

+1 508-517-7566